What is HC Wainwright’s Estimate for QUIT FY2026 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:QUIT) – Investment analysts at HC Wainwright dropped their FY2026 earnings estimates for Achieve Life Sciences in a report released on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($1.38) for the year, down from their previous forecast of ($1.02). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ Q4 2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.67) EPS and FY2028 earnings at $0.28 EPS.

A number of other research firms have also commented on QUIT. Zacks Research initiated coverage on shares of Achieve Life Sciences in a research note on Tuesday. They issued a “hold” rating for the company. Weiss Ratings assumed coverage on Achieve Life Sciences in a research report on Wednesday. They issued a “sell (d-)” rating for the company. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce”.

Achieve Life Sciences Trading Down 2.5%

QUIT stock opened at $6.29 on Friday. Achieve Life Sciences has a 52-week low of $2.62 and a 52-week high of $8.64. The company has a quick ratio of 0.95, a current ratio of 10.49 and a debt-to-equity ratio of 0.03.

About Achieve Life Sciences

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products. Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.